Immunoswitch Nanoparticles for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies face challenges due to the suppressive actions of the tumor microenvironment, requiring a priori knowledge of tumor antigens and leading to limited effectiveness and antigenic escape, with checkpoint blockade therapies showing incomplete response rates.
Innovation Solution
Development of immunoswitch particles that combine an inhibitory checkpoint signal, PDL1, with a co-stimulatory 4-1BB signal to T cells, bypassing the need for antigen knowledge and enhancing T cell activation by physically linking effector and target cells, thereby switching off inhibitory pathways and switching on stimulatory pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint blockade with monoclonal antibodies against PD-1 and PDL1 is used, then tumor growth is delayed and overall response rates increase to approximately 30%, but complete response rates remain as low as 5% and the tumor microenvironment upregulates immunosuppressive cytokines that diminish T cell cytotoxic effects
Solution Approach 1:
The invention segments the immunotherapy approach by using nanoparticles to deliver multiple distinct immunomodulatory agents simultaneously to the tumor microenvironment. The nanoparticle composition includes checkpoint inhibitors, cytokines, and co-stimulatory molecules that work in combination to overcome the suppressive effects that limit monotherapy response rates
Solution Approach 2:
The invention employs composite nanoparticle materials that can carry and deliver multiple therapeutic agents including checkpoint blockade antibodies, cytokines, and co-stimulatory signals. This composite approach allows simultaneous targeting of multiple immunosuppressive pathways while providing co-stimulatory signals to enhance T cell responses
2Adaptability or versatility
If adoptive cell transfer and T cell activation approaches are used, then personalized cancer therapeutics can be provided, but the cost, time, and difficulty increase significantly
Solution Approach 1:
The nanoparticle platform provides universal applicability across different cancer types and patients by delivering a combination of immunomodulatory agents that work through multiple pathways. The platform can be adapted to different tumor antigens and patient profiles without requiring complex personalized cell manipulation procedures
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that delivers immunomodulatory agents directly to the tumor microenvironment, eliminating the need for complex ex vivo T cell manipulation and reinfusion procedures. This mediator approach simplifies the treatment process while maintaining personalized therapeutic effects
3Productivity
If clonal population of T cells is activated against a single tumor antigen, then adaptive immune response is stimulated, but antigenic escape and growth of resistant tumor cell mutants are enabled
Solution Approach 1:
The invention merges multiple immunomodulatory mechanisms including checkpoint inhibition, cytokine delivery, and co-stimulatory signaling into a single nanoparticle platform. This combination approach activates diverse T cell populations through multiple pathways simultaneously, preventing the selective pressure that leads to antigenic escape
Solution Approach 2:
The nanoparticle platform provides dynamic immunomodulation by delivering multiple agents that work synergistically to activate and sustain diverse T cell responses. The combination therapy creates a moving target for tumor cells, making it difficult for them to develop resistance through single antigen mutation
4Strength
If tumor-targeting T cells are present, then cytotoxic effects can be exerted, but the tumor microenvironment upregulates immunosuppressive cytokines and surface antigens that diminish their effects
Solution Approach 1:
The nanoparticle formulation includes agents that preemptively counteract the immunosuppressive microenvironment before T cells can be suppressed. Checkpoint inhibitors and co-stimulatory molecules are delivered to block suppressive pathways in advance, preserving T cell cytotoxic function
Solution Approach 2:
The invention converts the immunosuppressive microenvironment from a harmful factor into a therapeutic target by using the same microenvironmental components (checkpoint molecules, cytokines) as delivery targets and mechanisms for the nanoparticle therapy, turning the suppressive landscape into an avenue for enhancing T cell activity
Data Source
AI summary
The presently disclosed subject matter relates to immunoswitch particles that switch off immunosuppressive pathways on tumor cells or immunosuppressive molecules induced by tumor cells in the tumor microenvironment, or virus infected cells or immunosuppressive molecules induced by virus infected cells in the microenvironment surrounding the virus infected cells, while simultaneously switching on co-stimulatory or co-inhibitory pathways on T cells, as well as method for converting immunosuppressive signals in cells, tissues, and subjects into stimulatory signals, and immunotherapy-based methods for treating cancer and chronic viral infections.